This message contains images. If you don't see images, click here to view.
Advertise in this news brief.

Text Version   RSS   Subscribe   Unsubscribe   Archive   Media Kit          February 24, 2015

Home  |   About ASHI  |   Education  |   Publications  |   Meetings  |   Careers  |   News  |   Lab Center

Proficiency Testing
Click here to place your 2015 Proficiency Testing order or to view your laboratory's previous Performance and Summary reports.
Renew Your Membership Now!
Doing so today so will help to avoid interruption accessing the ASHI Quarterly & ASHI-U for continuing education credits. Your Human Immunology subscription can also be renewed at this time


2015 Call for Award Nominations — DEADLINE June 1, 2015

Know someone who should be publicly acknowledged for his/her contributions to histocompatibility and immunogenetics? ASHI has opened nominations to the membership for the following awards!

ASHI RISING STAR AWARD An outstanding HLA technologist who has worked in the field fewer than three years and desires to pursue a career in HLA *Short essay* of fewer than four pages describing his/her current work in HLA and why he/she is interested in pursuing a career in HLA

*Essay must be written by the nominee and validated by his/her Lab Director
ASHI DISTINGUISHED SERVICE AWARD ASHI membership past or present, doctoral or non-doctoral. Creativity in moving ASHI in new directions, scientifically and as an organization

Service to ASHI

Educational contribution on behalf of ASHI

Other extraordinary contributions (please explain)
*Letter of nomination from an ASHI member

*Two additional supporting letters

*Candidate's curriculum vitae
ASHI DISTINGUISHED SCIENTIST AWARD *ASHI membership past or present, doctoral or non-doctoral

*Professional scientific accomplishments: theoretical and technical creativity

*Special contributions and achievements in their field of expertise

*Other extraordinary contributions (please explain)
*Letter of nomination from an ASHI member

*Two additional supporting letters

*Candidate's curriculum vitae

ASHI membership is not required
*Distinguished scientific accomplishments in the field of histocompatibility and immunogenetics

* Contributions to the advancement of histocompatibility and immunogenetics

*Other extraordinary contributions (please explain)
*Letter of nomination

*Two additional supporting letters (only one required if nominator is an ASHI member)

*Candidate's biosketch and curriculum vitae

ASHI membership (non-doctoral) is required.
*Contributions to advancement of technology and science of HLA immunogenetics

*Service to ASHI or ABHI as a committee member, director, officer, etc.

*Educational contributions on behalf of ASHI at a regional or national level

* Certification in histocompatibility

* Other extraordinary contributions (please explain)
*Letter of nomination from an ASHI member

*Two additional supporting letters

*Candidate's curriculum vitae

*Cannot have previously received the award

If you've submitted a nomination in the past and that nominee has not been recognized, please contact the ASHI office to update and resubmit the nomination.

Return nominations & supporting documentation by June 1, 2015 via email to: Katherine Miranda, ASHI Executive Director —

2015 Call for ASHI Board Nominations — Deadline May 4
The ASHI Nominations Committee encourages all ASHI members to nominate candidates for the available officer and board positions. If there are candidates you feel would be an asset to the ASHI Board of Directors, please complete and submit this nomination form to ASHI. All nominations must be accompanied by the signatures of at least 10 full or honorary members in good standing. Email endorsements are acceptable.

By March 23, the Nominations Committee will forward its preliminary slate of candidates to the ASHI membership. This will allow members time to submit additional nominations by the May 4 deadline.

Share this article:  

OPTN/UNOS policy and bylaw proposals
Distributed for Public Comment
Jan. 27, 2015

This document contains ten proposals being offered for public comment. These proposals were developed by OPTN/UNOS committees. When the public comment period ends on March 27, 2015, each sponsoring committee will review the feedback it received and consider modifications to the original proposals. The OPTN/UNOS Board of Directors may then review and vote on these proposals at its meeting on June 1-2, 2015.

Click here for more information

Share this article:  


The ASHI 2015 Regional Workshop registration is now open!

WORKSHOP 1: San Antonio, Texas
Click here to register now!

WORKSHOP 2: Philadelphia, Pennsylvania
Click here to register now!

Download your personal copy of the registration brochure now.


HLA class II genotypes are not associated with age related macular degeneration in a case-control, population-based study Human Immunlogy
Human Immunlogy
Multiple lines of evidence support an immunologic basis and genetic disposition for the development of age-related macular degeneration (AMD). Comprehensive human leukocyte antigens (HLA) class II typing at four loci (DRB1, DQA1, DQB1, and DPB1) was assessed using next generation sequencing methods and tested for association with age-related macular degeneration (AMD) in a case-control study of 456 AMD cases and 499 controls from the population-based Study of Osteoporotic Fractures (SOF) cohort. No statistically significant associations were identified for any of the class II loci and a previously identified association between DRB1*13:01 was not replicated in this dataset. These results reported here suggest that common HLA class II genetic variation does not contribute to AMD disease risk.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Click here
to visit the ASHI Insights archive page.

Growing wave of hospital, health system mega-mergers means changing dynamics for pathology, clinical lab medicine
Dark Daily
Large and financially-stable multi-hospital health systems are racing to form regional mega-systems. It's a strategy to get ahead of the Affordable Care Act's mandate to improve quality and increase efficiency through coordinated care across the entire care continuum. This growing national trend means further consolidation of clinical laboratory testing services within the merging organizations.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Stem cell transplants may work better than existing drug for severe multiple sclerosis
Medical Xpress
Stem cell transplants may be more effective than the drug mitoxantrone for people with severe cases of multiple sclerosis (MS), according to a new study published in the February 11, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology. The study involved 21 people whose disability due to MS had increased during the previous year even though they were taking conventional medications (also known as first-line treatments).
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

ASHI Insights
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Esther Cho, Content Editor, 469.420.2671  
Contribute news

Learn how to add us to your safe sender list so our emails get to your inbox.

This edition of ASHI Insights was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!
Recent issues
Feb. 10, 2015
Jan. 27, 2015
Jan. 13, 2015

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063